A Pilot Study of Docetaxel on a Bi-Weekly Schedule in the Treatment of Elderly Men With Hormone-Refractory Prostate Cancer (HRPC)
The information obtained from this trial will help determine the feasibility and safety of
administering docetaxel at various dosing levels on a bi-weekly schedule in this patient
population. If the data from this phase I trial are encouraging, a phase II trial will be
conducted to further assess the efficacy of this dosing schedule.
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the maximum tolerated dose (MTD) of docetaxel on a bi-weekly schedule in the treatment of elderly men with hormonal refractory prostate cancer (HRPC).
William Ershler, MD
Geriatric Oncology Consortium
United States: Institutional Review Board
|Baltimore, Maryland 21287|